Cytotoxic effect of dibutyryl cAMP, phorbol-12-myristate-13-acetate and lipopolysaccharide, but not interferon-γ, on promonocytic cell lines in vitro

Anti-Cancer Drugs

Volumn 8, Issue 6, 1997, Pages 618-622

  Hetland, G ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cytotoxicity; Dibutyryl cAMP; Lipopolysaccharide,; Mono Mac 6 cells; Phorbol 12 myristate 13 acetate; U937 cells

Indexed keywords

BUCLADESINE; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; PHORBOL 13 ACETATE 12 MYRISTATE; RECOMBINANT GAMMA INTERFERON;

ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL STRAIN HL 60; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

BUCLADESINE; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE; CELL SURVIVAL; HUMANS; INTERFERON TYPE II; LIPOPOLYSACCHARIDES; MONOCYTES; PROTEIN BIOSYNTHESIS; PROTEINS; TETRADECANOYLPHORBOL ACETATE;

EID: 0030770599     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199707000-00010     Document Type: Article

References (24)

1. Kay GE, Lane BC, Snyderman R. Induction of selective biological responses to chemoattractants in a human monocyte-like cell line. Infect Immunol 1983; 41: 1166-74.
2. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991; 349: 614-7.
3. Cheng T, Erickson-Miller CL, Li C, et al. IHMeg-1, a cell line derived from a CML patient, is capable of monocytic and megakaryocytic differentiation. Leukemia 1995; 9: 1257-63.
4. Schwende H, Fitzke E, Ambs P, Dieter P. Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D3. J Leukocyte Biol 1996; 59: 555-61.
5. Breitman TR, Hemmi H, Imaizumi, M. Induction by physiological agents of differentiation of the human leukemia cell line HL-60 to cells with functional characteristics. Prog Clin Biol Res 1986; 226: 215-33.
6. Treon SP, Broitman SA. Beneficial effects of post-transfusional hepatitis in acute myelogeneous leukemia may be mediated by lipopolysaccharides, tumor necrosis factor α and interferon γ. Leukemia 1992; 6: 1036-42.
7. Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 1993; 11: 571-611.
8. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-γ as the lymphokine that activates human macrophage oxidative metabolism and anti-microbial activity. J Exp Med 1983; 158: 670-89.
9. Zeigler-Heitbrock HW, Thiel E, Futterer A, Herzog V, Wirtz A, Riethmuller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 1988; 41: 456-61.
10. Hetland G, Guinn K, Hugli TE. Effect of formyl peptide-toxin conjugates on myeloid cancer cell lines in vitro. Int J Immunother 1995; 11: 85-93.
11. Hetland G, Hugli TE. Cytotoxic effect of radiolabeled C5a on U937 cells in vitro. Cancer Lett 1996; 110: 97-103.
12. Burg M, Martin U, Rheinheimer C, Köhl J, et al. IFN-γ upregulates the human C5a receptor (CD 88) in myeloblastic U937 cells and related cell lines. J Immunol 1995; 155: 4419-26.
13. Chateau MT, Ginestier-Verne C, Chiesa J, Caravano R, Bureau JP. Dimethyl sulfoxide-induced apoptosis in human leukemic U937 cells. Anal Cell Pathol 1996; 10: 75-84.
14. Benito A, Grillot D, Nunez G, Fernandez-Luna JL. Regulation and function of Bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells. Am J Pathol 1995; 146: 481-90.
15. Sundström C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976; 17: 565-77.
16. Bøyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968; 21(suppl 97): 77-89.
17. Li J, Hui N, Zhu L. Synergistic effects of tumor necrosis factor, interferon-γ and chemotherapeutic drugs on human ovarian cancer cell lines in vitro. Chung Hua Chung Liu Tsa Chih 1995; 17: 429-31.
18. Koperski MS, Lipton A, Harvey HA, Kumar R. Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines. Anticancer Res 1996; 16: 433-6.
19. Lotem J, Sachs L. Interferon-γ inhibits apoptosis induced by wild-type p53, cytotoxic anti-cancer agents and viability factor deprivation in myeloid cells. Leukemia 9: 685-92.
20. Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M, Results of interferon-alpha therapy in patients with chronic myelogeneous leukemia 60 years of age and older. Am J Med 1996; 100: 452-5.
21. Bettaieb A, Record M, Come MG, et al. Opposite effects of tumor necrosis factor alpha on shingomyelin-ceramide pathway in two myeloid leukemia cell lines: role of transverse sphingomyelin distribution in the plasma membrane. Blood 1996; 88: 1465-72.
22. Packham G, Porter CW, Cleveland JL. c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Oncogene 1996; 13: 461-9.
23. Hetland G, Johnson E, Røyset P, Eskeland T. Human alveolar macrophages and monocytes generate the functional classical pathway of complement in vitro. Acta Path Microbiol Immunol Scand 1987; 95: 117-22.
24. Afford SC, Pongracz J, Stockley RA, Crocker J, Burnett D. The induction by human interleukin-6 of apoptosis in the promonocytic cell line U927 and human neutrophils. J Biol Chem 1992; 267: 21612-6.